Ehave Launches Baseline Concussion Assessment Tool on Ehave Connect
?Ehave, Inc.?(OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced that the Company has created a baseline concussion assessment tool that is now available on?Ehave Connect, a digital “App Store” designed to enhance access to a broad array of content offered by Ehave and its growing roster of mental healthcare partners. ?The test will record baseline concussion symptoms using validated cognitive assessments and, via the robust Ehave Core Platform, provide extensive information about the athlete’s history with concussions upon repeat assessment following acute injury.? The platform can also be used to track treatment progress to help guide return-to-sport and return-to-school strategies.
Baseline concussion tests are an important piece in concussion management, and an area that is uniquely suited to the benefits of Ehave’s mental health platform. Baseline assessments are typically taken as a preventative measure prior to a sport season. The same test can be taken again by the athlete/caregiver after an injury to provide comparative pre- and post-injury scores. Comparing post-injury test scores of an individual to their own baseline test scores as opposed to the general population is considered best practice.
Prateek Dwivedi,?CEO of Ehave, said, “Mild traumatic brain injury (mTBI), or concussion, is the most common type of traumatic brain injury and is part of the target group of mental and cognitive conditions that Ehave is currently focused on. Initially, we plan to focus marketing of our baseline concussion test on school boards and amateur sports leagues where the need is greatest. Separately, Ehave is currently exploring Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis’s potential ability to provide relief to persons suffering from post-traumatic stress disorder (“PTSD”). This use of our platform may be extended to mTBI, where early research has indicated the potential utility of cannabinoids in the treatment of both acute and chronic traumatic brain injury.”